DBV Technologies S.A..
DBVT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
DBV Technologies S.A. is a French biopharmaceutical company focused on the discovery and development of innovative, safe, and convenient immunotherapies for the treatment of food allergies and other immunological diseases. The company's lead product candidate is Viaskin Peanut, an investigational ep...Show More
Better Health for All
0
DBV Technologies' core business is entirely focused on developing treatments for food allergies, with its Viaskin Peanut patch showing revolutionary health benefits in clinical trials. The 3-year results from the EPITOPE Phase 3 Open-Label Extension Study demonstrate continued improvement, with 68.2% of toddlers completing oral food challenges at 36 months and 83.5% reaching an eliciting dose of ≥1000mg.
1
The company invests significantly in health innovation, with R&D expenses increasing by $29.1 million in 2024,
2
and its entire business model is dedicated to developing novel epicutaneous immunotherapy. The company targets vulnerable populations, specifically children and toddlers with food allergies, with studies focused on these age groups.
3
The Viaskin Peanut patch is also presented as a preventative measure to reduce the risk of allergic reactions.
4
However, the company's safety record shows significant concerns, with 100% of participants in the EPITOPE trial experiencing adverse events and 8.6% experiencing serious adverse events.
5
The company has also faced notable regulatory challenges, including a Complete Response Letter from the FDA in 2020
6
and a partial clinical hold on the VITESSE trial in 2021,
7
indicating issues with risk transparency and regulatory compliance. While the company acknowledges the impact of peanut allergy on quality of life and anxiety,
8
there is no evidence of practical support or dedicated programs for mental health. The company conducts clinical trials under Good Clinical Practice standards
9
but has faced regulatory holds and requirements for additional safety data,
10
indicating some gaps in ethical conduct.
Fair Money & Economic Opportunity
0
No evidence available to assess DBV Technologies S.A. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
The CEO total compensation to median employee compensation ratio was 2.931640 in 2022.
1
Employee reviews on Glassdoor indicate an overall rating of 3.4 out of 5 stars, with 63% of employees recommending working at the company.
2
Specific category ratings include 3.5 for culture and values, 3.3 for diversity, equity & inclusion, 2.8 for work/life balance, 3.6 for senior management, and 2.7 for compensation and benefits.
3
The CEO approval rating is 27%.
4
Fair Trade & Ethical Sourcing
0
No quantitative data or specific evidence related to fair trade and ethical sourcing, such as fair-trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, was found in the provided articles for DBV Technologies S.A.
1
Several articles explicitly state the absence of such metrics, or refer to policies without providing performance data.
Honest & Fair Business
-40
DBV Technologies has a formal whistleblower policy, including a 24/7 third-party operated Ethics & Compliance Integrity Hotline available online and by phone, with a commitment that personnel acting in good faith will not be subject to retaliation.
1
All personnel must certify annually that they have read and intend to comply with the Code of Ethics and Business Conduct, which was updated in February 2021.
2
The company filed its Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC on April 11, 2025, which was subsequently amended twice on April 28, 2025, and May 14, 2025.
3
DBV's Code of Ethics and Business Conduct, updated in February 2021, includes an anti-corruption policy that prohibits giving or offering anything of value to influence acts or decisions, particularly with healthcare professionals and government officials.
4
It also addresses compliance with laws such as the FCPA and UK Bribery Act, and requires annual acknowledgment from all personnel.
5
Kind to Animals
0
No evidence available to assess DBV Technologies S.A. on Kind to Animals.
No War, No Weapons
0
No specific, concrete data points or explicit statements regarding DBV Technologies' involvement in arms manufacturing, military contracts, conflict facilitation, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' value were found in the provided articles. The articles primarily focus on the company's biopharmaceutical activities, regulatory agreements, and financial performance, explicitly stating that no relevant quantitative data for these metrics was available.
1
Planet-Friendly Business
0
The provided articles, primarily focusing on financial performance and stock market analysis, do not contain any specific data related to DBV Technologies' environmental performance or stewardship. There is no information available regarding greenhouse gas emissions, renewable energy use, water consumption, waste management, climate targets, or any environmental compliance records.
Respect for Cultures & Communities
0
DBV Technologies S.A. provides an Ethics & Compliance Integrity Hotline with separate phone numbers for Canada, supporting both English and French as primary languages.
1
No other specific, concrete evidence was found in the provided articles to assess the company against the remaining Key Performance Indicators for the 'Respect for Cultures & Communities' value. The articles primarily focus on financial information, clinical trial pipelines, governance, and general ethical conduct, without detailing specific community engagement, cultural preservation, or local impact initiatives.
Safe & Smart Tech
0
DBV Technologies provides outstanding user data control, outlining rights for California residents under CCPA (notice, access, deletion, opt-out of sale, non-discrimination) and for EU/EEA residents (access, rectification, objection, restriction, withdrawal of consent, data portability, deletion, and the ability to define guidelines for personal data in the event of death).
1
The company states it does not sell personal information according to its understanding of the CCPA.
2
However, its data minimization practices are limited, with traffic data retained for 13 months, marketing data for 3 years, legal claims evidence for 5 years, and accounting data for 10 years.
3
The company demonstrates good compliance with the CCPA and addresses rights afforded to individuals based in the EU/EEA, indicating an effort to comply with GDPR, and implements standard contractual clauses for data transfers outside the EU/EEA.
4
The company guarantees that all personnel processing personal data will respect internal rules and procedures, including security measures.
5
It also has a risk management process for identifying, assessing, and managing cybersecurity threats, including automated tools, threat reports, scans, internal audits, and vulnerability assessments.
6
The company's privacy policy and code of ethics indicate an intent to integrate privacy considerations into its operations.
Zero Waste & Sustainable Products
-30
The company's Viaskin patch is designed for single use and disposal after 24 hours, indicating a linear take-make-dispose approach.
1
DBV Technologies states a commitment to conducting business in an environmentally responsible way, minimizing environmental impacts, and adhering to applicable environmental laws and regulations.
2
The company is also committed to disposing of all waste, including allergens in its Viaskin patch, through safe and responsible methods.
3